Portfolio Lab

INSMED Inc

  • Stock
  • Ticker INSM
  • ISIN US4576693075
  • Nasdaq

Health care · Pharmaceuticals · USA

$141.33 −2.17%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of INSMED Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

INSMGlobal equities (VT)

$10,000 grew to $96,669. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −64.8% in 12/2018, measured from the peak in 01/2018. It took 25 months to get back to the old peak.

1-year return
−29.2%
5-year return p.a.
+35.9%
10-year return p.a.
+25.5%
Volatility p.a.
82.9%
Largest decline
−64.8%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue10493107142264306425524
Gross profit787279113220259358446
Operating income-230-248-313-366-320-153-1.5-89
EBITDA-229-246-310-364-316-1501.6-86
Net income-236-257-322-370-328-164-13-100
Earnings per share-1.30-1.42-1.70-1.75-1.53-0.76-0.06-0.46
Balance sheet
Total assets2,0251,8032,4802,3612,2652,0762,1032,226
Liabilities1,7401,7041,2301,4151,5261,3711,3451,500
Equity285991,250946739705757726
Cash5554031,284335510582545397
Long-term debt1,1031,105539540541542544545
Cash flow
Operating cash flow-196-262-206-220-248-223-89-36
Capital expenditure-6.8-10-3.5-2.4-17-3.5-6.3-5.6
Free cash flow-203-272-209-222-264-226-95-42

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +152.1%, weakest 2018 at −57.9%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026−$0.46
6 Aug 2026−$0.06
7 May 2026−$0.76
19 Feb 2026−$1.53
30 Oct 2025−$1.75
7 Aug 2025−$1.70
8 May 2025−$1.42
20 Feb 2025−$1.30
31 Oct 2024−$1.27
8 Aug 2024−$1.94
9 May 2024−$1.06
22 Feb 2024−$1.28

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€28bn
Market cap in trading currency
$31.0bn
Enterprise value
$30.4bn
P/E
–
P/S
20.40
P/B
42.69
EV/Sales
20.01
EV/EBITDA
–
Earnings yield
–
FCF yield
-2.0%

Results (last four quarters)

Revenue
$1.52bn
Gross profit
$1.28bn
EBITDA
−$551m
Net income
−$606m
Earnings per share
−$2.81
Revenue per share
$6.93
Revenue growth
+268.4%
Earnings growth
–

Profitability

Gross margin
84.4%
Operating margin
-37.1%
Net margin
-39.9%
Return on equity
-72.5%
Return on assets
-27.2%

Balance sheet and cash flow

Cash
$1.15bn
Cash per share
$5.23
Financial debt
$547m
Debt/equity %
75
Current ratio
2.86
Book value per share
$3.31
Operating cash flow
−$596m
Free cash flow
−$628m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
219m
Volume
6.21m
Avg. volume 3 months
2.79m
Relative volume
2.0

Price and technicals

Price
$141.33
1 day
−2.2%
52-week high
$211.41
52-week low
$91.88
Distance to 52-week high
−33.1%
Distance to 52-week low
+53.8%
Distance to 50-day line
+27.2%
Distance to 200-day line
+15.3%
RSI (14)
73
Volatility 1M
87.0%

Performance

1 week
+16.6%
1 month
+48.7%
3 months
+14.0%
6 months
+33.0%
YTD
−18.8%
1 year
−30.6%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has INSM performed since 11/2016?

$10,000 grew to $96,669 by 20 Nov 2026, which is +25.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is INSM?

Volatility was 82.9% per year, measured on monthly returns. The largest decline from a peak was −64.8%, with the low in 12/2018.

How does INSM compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, INSM returned +25.5% at 82.9%. The correlation of monthly returns was 0.27; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

INSMED Inc (INSM): Return and risk | Portfolio Lab